English
日本語
한국어
简体中文
繁體中文
Italiano
español
Deutsch
Русский
With the help of a university professor and a psychiatrist, I created a project to discuss the function of pharmaceuticals in modifying synaptic plasticity linked with aging diseases, particularly Alzheimer's disease, and I presented it to the health comm
Detalles de la lección
This presentation was developed in English.
The onset of neurodegenerative disorders has increased exponentially with age, suggesting that the brain is particularly susceptible to the aging process. Alzheimer's disease starts with an asymptomatic stage and biomarker evidence of the condition and progresses by expressing mild cognitive and/or neurobehavioral abnormalities until it reaches the state of dementia.
The hippocampus, essential in the regulation of learning and memory, is the brain structure most affected by Alzheimer's disease. It exhibits incredible structural and functional plasticity in response to environmental changes, making it an important target for research.
Aducanumab, a kind of human monoclonal antibody, has been approved by the U.S. Food and Drug Administration to treat Alzheimer's patients. It will be available in the US from June 7, 2021.
Aducanumab has emerged as the most promising treatment for AD during the past ten years. Other non-pharmacological therapies, stem cell therapy and hyperbaric oxygen therapy are two potential candidates to help prevent and/or treat Alzheimer's.
Early diagnosis of AD allows access to treatment options that do not cure the disease but reduce cognitive and functional decline at an early stage. It also opens new horizons for people to change their lifestyle to prevent aging related diseases and stay healthy longer.
The hippocampus, essential in the regulation of learning and memory, is the brain structure most affected by Alzheimer's disease. It exhibits incredible structural and functional plasticity in response to environmental changes, making it an important target for research.
Aducanumab, a kind of human monoclonal antibody, has been approved by the U.S. Food and Drug Administration to treat Alzheimer's patients. It will be available in the US from June 7, 2021.
Aducanumab has emerged as the most promising treatment for AD during the past ten years. Other non-pharmacological therapies, stem cell therapy and hyperbaric oxygen therapy are two potential candidates to help prevent and/or treat Alzheimer's.
Early diagnosis of AD allows access to treatment options that do not cure the disease but reduce cognitive and functional decline at an early stage. It also opens new horizons for people to change their lifestyle to prevent aging related diseases and stay healthy longer.
Política de cancelación del(de la) tutor/a
Antes de que la solicitud haya sido confirmada.
- Es posible hacerlo en cualquier momento.
Luego de que la solicitud de clase haya sido confirmada
- Menos de 24 horas antes de que la clase de comienzo→ Se perderá el 50% del importe de la clase
- No-Show→ Se perderá el 100% del importe de la clase
Todas las clases del (de la) tutor/a
All Lessons
-
-
PORTUGUESE STEP BY STEP (SHORT VERSION)
¿Tienes una agenda ocupada? Te ayudará si aun hablas sólo un poquito cada día. Esta es una breve lección de 15 minutos.15min 700P -
-
ENGLISH STEP BY STEP (SHORT VERSION)
¿Tienes una agenda ocupada? Te ayudará si aun hablas sólo un poquito cada día. Esta es una breve lección de 15 minutos.15min 600P -
ENGLISH STEP BY STEP
This is a 30 minute break from your daily routine to practice your English speaking skills. Let's talk!30min 1,200P -
Professional English Writing and Communication
"Professional English Writing and Communication" is a class designed to help non-native English speakers improve their ability to write effective and clear emails and paperwork in English.30min 1,200P
